2023
High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
Robert M, Rüschoff J, Jasani B, Graham R, Badve S, Rodriguez-Justo M, Kodach L, Srivastava A, Wang H, Tang L, Troncone G, Rojo F, Van Treeck B, Pratt J, Shnitsa I, Kumar G, Karasarides M, Anders R. High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma. Modern Pathology 2023, 36: 100154. PMID: 36925069, DOI: 10.1016/j.modpat.2023.100154.Peer-Reviewed Original ResearchConceptsCombined positive scorePD-L1 expressionCheckpoint inhibitor therapyPD-L1Tumor cellsImmune cellsIntraclass correlation coefficientInhibitor therapyInterpretation of PD-L1 expressionPD-L1 combined positive scoreInterobserver variabilityBiopsy samplesEvaluate PD-L1 expressionImmune checkpoint inhibitor therapyInterpathologist agreementProgrammed death-ligand 1PD-L1 immunohistochemistryDeath-ligand 1Variable intensity of stainingIntensity of stainingPositive scoresRetrospective histologic reviewPretreatment biopsiesTumor stainingHistologic review
2005
The Nuclear Transcription Factor κB/bcl-2 Pathway Correlates with Pathologic Complete Response to Doxorubicin-Based Neoadjuvant Chemotherapy in Human Breast Cancer
Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM, Singletary SE, Hortobagyi GN, Pusztai L, Cristofanilli M, Sahin AA. The Nuclear Transcription Factor κB/bcl-2 Pathway Correlates with Pathologic Complete Response to Doxorubicin-Based Neoadjuvant Chemotherapy in Human Breast Cancer. Clinical Cancer Research 2005, 11: 8398-8402. PMID: 16322301, DOI: 10.1158/1078-0432.ccr-05-0885.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAntineoplastic Combined Chemotherapy Protocolsbcl-2-Associated X ProteinBreast NeoplasmsCell NucleusChemotherapy, AdjuvantCyclophosphamideCytoplasmDoxorubicinFemaleFluorouracilHumansMiddle AgedNeoadjuvant TherapyNeoplasm StagingNF-kappa BProto-Oncogene Proteins c-bcl-2Signal TransductionSurvival RateTreatment OutcomeConceptsPathologic complete responseHuman breast cancerNF-kappaBNeoadjuvant chemotherapyComplete responseNeoadjuvant doxorubicinBcl-2Poor responseBreast cancerAnthracycline-based neoadjuvant chemotherapyNF-kappaB.Bcl-2-positive tumorsHuman breast cancer samplesBreast cancer responseClinical outcome dataTranscription factor NF-kappaBBreast cancer pathologistNuclear factor-kappaBBreast cancer samplesPCR ratePositive tumorsChemotherapy responseTumor stainingImmunohistochemical stainingCancer response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply